UNSPSC 41202037: Listeria spp. serological reagents

In this classification, Listeria genus serological reagents are devices used in test to identify specific Listeria genus antibodies in serum. US FDA regulates Listeria genus serological reagents under 21 CFR 866.3355 and under FDA product code GSI.

UNSPSC 41202037 Listeria spp. serological reagents is a Commodity code that covers diagnostic testing supplies and reagents for infectious disease screening and confirmation across state and local public health and criminal justice laboratories. Recent opportunities under this code show state and local governments purchasing HIV, syphilis, and sexually transmitted infection (STI) testing kits and reagents; drug testing supplies and screening systems; and laboratory services supporting disease surveillance, offender monitoring, and clinical diagnostic functions. Issuing bodies include state departments of public health (Illinois Department of Public Health), county health care services and community supervision agencies (Collin County in Texas, Gwinnett County in Georgia), city public health programs (Austin), and state corrections departments (Texas Department of Criminal Justice). Illinois and Texas dominate recent activity, with multiple large-volume procurements for rapid diagnostics and analyzer-specific consumables.

Representative opportunities illustrate the scope. The Illinois Department of Public Health issued a change order in September 2026 (due October 13, 2026) increasing annual volumes for Hologic NG/CT (gonorrhea/chlamydia) testing under an IFB to 25,000 tests and 30,000 collection kits, raising the five-year contract cost from $525,000 to $900,000. In May 2026, IDPH issued an emergency sole-source procurement to Abbott Laboratories for HIV and syphilis reagent kits and maintenance services totaling $38,079.50 to maintain CLIA certification at the Carbondale Laboratory. Collin County issued an RFP in September 2026 (due July 23, 2026) for offender specimen collection and drug testing services, with immunoassay screening and LC/MS/MS or GC/MS confirmation across two sites, estimated at $600,000 annually. The City of Austin posted an IFB in June 2026 (rebid in August 2026) for rapid HIV Type 1 and Type 2 test kits (Abbott Determine brand) in quantities of approximately 375 kits and 79 control kits annually. Gwinnett County, Georgia solicited drug testing supplies for an existing drugs of abuse analyzer in September 2026 (due October 14, 2026), with limited scope details available.